Patent · US Active

Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein

US9840550B2 · kind B2 · utility

0Cited by
0References
6Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 1, 2013
Grant dateDec 12, 2017
Priority date
Expiry dateOct 1, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/76
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention deals with innovative compounds and compositions for preventing and/or treating a newly discovered detrimental mechanism, which blocks the endogenous myelin repair capacity of the adult nervous system (NS) in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.